๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Prevalence of hepatitis E virus infection in liver transplant recipients

โœ Scribed by Elizabeth B. Haagsma; Hubert G. M. Niesters; Arie P. van den Berg; Annelies Riezebos-Brilman; Robert J. Porte; Harry Vennema; Johan H. J. Reimerink; Marion P. G. Koopmans


Publisher
John Wiley and Sons
Year
2009
Tongue
English
Weight
128 KB
Volume
15
Category
Article
ISSN
1527-6465

No coin nor oath required. For personal study only.

โœฆ Synopsis


Hepatitis E virus (HEV) infection is known to run a self-limited course. Recently, chronic hepatitis E has been described in several immunosuppressed patients after solid organ transplantation. The prevalence of HEV infection after transplantation, however, is unknown. We studied HEV parameters [HEV RNA, HEV immunoglobulin M (IgM), and HEV immunoglobulin G (IgG) by enzyme-linked immunosorbent assay and confirmatory immunoblotting] in a cohort of 285 adult liver transplant recipients. The most recent freeze-stored sera were investigated, and if they were positive, a retrospective analysis was performed. Samples from 274 patients (96.1%) tested negative for all HEV parameters. This included a patient described earlier as having experienced an episode of chronic HEV hepatitis in the past. One patient was found positive for HEV RNA without HEV antibodies. She presently suffers from chronic HEV hepatitis and has also been described before. Sera from 9 patients tested positive for HEV IgG without HEV IgM or HEV RNA. Six of these 9 patients (2.1% of the total) were found to have HEV IgG antibodies in retrospect related to an HEV infection at some time pre-transplant as they also tested positive in a pretransplant serum sample. One of these 9 patients suffered in retrospect from a chronic HEV infection with mild hepatitis between 2 and 5 years after liver transplantation on the basis of the course of HEV RNA, IgM, and IgG, aminotransferases, and liver histology. Overall, the prevalence of acquired HEV hepatitis after liver transplantation was 1% in this cohort. We conclude that liver transplant recipients have a risk for chronic HEV infection, but the prevalence is low.


๐Ÿ“œ SIMILAR VOLUMES


Chronic hepatitis E virus infection in l
โœ Elizabeth B. Haagsma; Arie P. van den Berg; Robert J. Porte; Cornelis A. Benne; ๐Ÿ“‚ Article ๐Ÿ“… 2008 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 318 KB ๐Ÿ‘ 1 views

Hepatitis E virus (HEV) infection is known to run a self-limiting course. Sporadic cases of acute hepatitis due to infection with HEV genotype 3, present in pig populations, are increasingly recognized. Zoonotic transmission seems infrequent. The entity of unexplained chronic hepatitis after liver t

Hepatitis E virus infection as a cause o
โœ Sven Pischke; Pothakamuri V. Suneetha; Christine Baechlein; Hannelore Barg-Hock; ๐Ÿ“‚ Article ๐Ÿ“… 2010 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 256 KB ๐Ÿ‘ 2 views

Hepatitis E virus (HEV) infection induces self-limiting liver disease in immunocompetent individuals. Cases of chronic hepatitis E have recently been identified in organ transplant recipients. We questioned if chronic hepatitis E plays a role in graft hepatitis after liver transplantation in a low e

Ganciclovir treatment of hepatitis B vir
โœ R G Gish; J Y Lau; L Brooks; J W S Fang; S L Steady; J C Imperial; R Garcia-Kenn ๐Ÿ“‚ Article ๐Ÿ“… 1996 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 366 KB ๐Ÿ‘ 2 views

To determine the safety and efficacy of ganciclovir usually experience progressive liver disease over an treatment of hepatitis B virus (HBV) infection after liver accelerated time course and pose a difficult managetransplantation, nine patients (seven males, two females; ment challenge. The treatm

Treating hepatitis C infection in liver
โœ Norah A. Terrault; Marina Berenguer ๐Ÿ“‚ Article ๐Ÿ“… 2006 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 192 KB ๐Ÿ‘ 1 views

Chronic infection with hepatitis C virus (HCV) is a growing problem worldwide, with up to 300 million individuals infected, and those with chronic infection are at risk for cirrhosis and hepatocellular carcinoma. HCV infection is the most common indication for liver transplantation in the United Sta

Rimantadine for treatment of hepatitis C
โœ Sherman, Kenneth E. ;Sickler, Joelle ;Aranda-Michel, Jaime ;Weber, Frederick L. ๐Ÿ“‚ Article ๐Ÿ“… 1999 ๐Ÿ› Wiley (John Wiley & Sons) ๐ŸŒ English โš– 61 KB ๐Ÿ‘ 2 views

Hepatitis C recurrence after liver transplantation is a serious problem, leading to increased graft loss and morbidity in some individuals. Treatment with interferon and other agents is controversial and not highly efficacious. The use of an effective antiviral agent to reduce or eliminate viral bur

Fibrosing cholestatic hepatitis in renal
โœ Delladetsima, Johanna K. ;Boletis, John N. ;Makris, Fotis ;Psichogiou, Mina ;Kos ๐Ÿ“‚ Article ๐Ÿ“… 1999 ๐Ÿ› Wiley (John Wiley & Sons) ๐ŸŒ English โš– 445 KB

Fibrosing cholestatic hepatitis (FCH) has been described as a specific manifestation of hepatitis B virus (HBV) infection in liver allograft recipients characterized by a rapid progression to liver failure. Only sporadic cases have been reported in other immunocompromised groups infected with HBV an